Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.71 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415752 | 0.92 | HTT (0.61) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL26607461 | 0.88 | ALDH1A1 (0.75) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL16739563 | 0.87 | KCNMA1 (0.63) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL11659267 | 0.86 | ALDH1A1 (0.64) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL15156377 | 0.86 | KMT2A (0.56) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL10574218 | 0.85 | MAPT (0.54) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL10573721 | 0.84 | MAPT (0.53) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL30573735 | 0.83 | ALDH1A1 (0.64) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL5492605 | 0.83 | ALDH1A1 (0.64) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL2282371 | 0.81 | MAPT (0.68) | HTTNPC1RAB9AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809655-B1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8927587-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| EP-2809655-A1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Inc (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20130274243-A1 | Chemical Compounds | PFIZER LTD (GB) | 2013-10-17 | — | — | US | disclosed |
| WO-2013114250-A1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-0616807-B1 | Benzimidazole useful in the treatment of central nervous system disorders | NEUROSEARCH AS (DK) | 1998-07-08 | — | — | EP | disclosed |
| US-5554632-A | CENTRAL NERVOUS SYSTEM | NEUROSEARCH A/S (DK) | 1996-09-10 | — | — | US | disclosed |
| US-5554630-A | TREATING ANXIETY, CONVULSIONS AND SLEEP DISORDERS IN LIVING ANIMALS BY MODULATION OF THE BENZODIAZEPINE RECEPTOR OF THE CENTRAL NERVOUS SYSTEM WITH 1-/3-HETEROCYCLYLPHENYL/-BENZIMIDAZOLES | NEUROSEARCH A/S (DK) | 1996-09-10 | — | — | US | disclosed |
| EP-0616807-A1 | Benzimidazole useful in the treatment of central nervous system disorders | NEUROSEARCH A/S (DK) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274243-A1 | Chemical Compounds | SCN8A, SCN5A, KCNJ8 | MAPK1 1602/4885ALDH1A1 1502/4885HTT 2139/4885 |
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | MAPK1 3885/4885ALDH1A1 151/4885HTT 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.